ABSTRACT
Summary The identification of tumor antigens has generated a resurgence of interest in cancer immunotherapy. However, recent studies from both human and animal models indicate that therapeutic strategies mainly focusing on the exclusive use of CD8 T cells (and MHC class Irestricted tumor antigens) may not generate effective immunity against cancer cells. Thus, the identification of MHC class II-restricted tumor antigens, which are capable of stimulating CD4 T cells, might provide opportunities for developing effective cancer vaccines. This chapter will discuss the latest progress in identifying melanoma antigens recognized by CD4 T cells.
